American International Group, Inc. Ikena Oncology, Inc. Transaction History

American International Group, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.27 - $2.0 $166 - $262	-131 Reduced 0.85%	15,255 $21,000
Q4 2023 Feb 13, 2024	BUY	$1.33 - $4.4 $3,979 - $13,164	2,992 Added 24.14%	15,386 $30,000
Q3 2023 Nov 13, 2023	BUY	$4.09 - $6.43 $8,842 - $13,901	2,162 Added 21.13%	12,394 $53,000
Q2 2023 Aug 04, 2023	BUY	$3.5 - $7.31 $35,812 - $74,795	10,232 New	10,232 $67,000
Q2 2022 Aug 12, 2022	SELL	$3.23 - $7.4 $44,438 - $101,809	-13,758 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.61 - $13.85 $5,424 - $13,392	-967 Reduced 6.57%	13,758 $84,000
Q4 2021 Feb 11, 2022	BUY	$10.52 - $16.96 $95,079 - $153,284	9,038 Added 158.92%	14,725 $185,000
Q3 2021 Nov 12, 2021	BUY	$9.82 - $15.23 $5,950 - $9,229	606 Added 11.93%	5,687 $72,000
Q2 2021 Aug 13, 2021	BUY	$13.27 - $26.0 $67,424 - $132,106	5,081 New	5,081 $71,000

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $56.9M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.